Pacific Biosciences Of California (PACB) Other Accumulated Expenses (2011 - 2026)

Pacific Biosciences Of California has reported Other Accumulated Expenses for 16 years, with the latest figure at $1.2 million in Q1 2026.

• For the quarter ending Q1 2026, Other Accumulated Expenses fell 77.83% year-over-year to $1.2 million; the trailing twelve-month figure through Mar 2026 stood at $1.2 million (down 77.83% YoY), and the FY2025 full-year result was $2.0 million, down 37.0% from the prior year.
• Other Accumulated Expenses for Q1 2026 stood at $1.2 million, down from $2.0 million in the prior quarter.
• The five-year high for Other Accumulated Expenses was $8.3 million in Q4 2023, with the low at $783000.0 in Q3 2024.
• Average Other Accumulated Expenses over 5 years is $4.3 million, with a median of $4.6 million recorded in 2022.
• Year-over-year, Other Accumulated Expenses jumped 103.31% in 2022 and plunged 84.85% in 2024.
• Tracing PACB's Other Accumulated Expenses over 5 years: stood at $7.2 million in 2022, then advanced by 15.11% to $8.3 million in 2023, then sank by 61.28% to $3.2 million in 2024, then sank by 37.0% to $2.0 million in 2025, then tumbled by 39.19% to $1.2 million in 2026.
• The last three Other Accumulated Expenses figures came in at $1.2 million (Q1 2026), $2.0 million (Q4 2025), and $1.0 million (Q3 2025), per Business Quant data.

Peer Comparison